Literature DB >> 7856833

Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions.

F L Njoo1, W M Beek, H J Keukens, H van Wilgenburg, J Oosting, J S Stilma, A Kijlstra.   

Abstract

Ivermectin treatment of onchocerciasis patients can be accompanied by adverse reactions. Not much is known concerning the pathogenesis of these reactions. Previous studies have demonstrated that the occurrence and extent of adverse reactions are related to infection intensity. However, some severely infected patients experience relatively few adverse effects. The aim of the present study was to investigate whether this seeming discrepancy could be due to diminished ivermectin absorption. Ivermectin concentrations one and two days after treatment were measured by high-performance liquid chromatography in sera of 71 skin snip-positive onchocerciasis patients (21 without reactions, 25 with mild reactions, 14 with moderate reactions, and 11 with severe reactions). The overall mean +/- SD ivermectin concentrations one and two days after a single oral dose (150 micrograms/kg) were 16.4 +/- 6.4 and 6.6 +/- 3.1 ng/ml, respectively. The overall mean +/- SD half-life was estimated to be 19.9 +/- 8.6 hr. The data presented did not show a relationship between ivermectin concentrations and the grade of adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7856833     DOI: 10.4269/ajtmh.1995.52.94

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  6 in total

Review 1.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

2.  Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

Authors:  Michel Boussinesq; Jacques Gardon; Nathalie Gardon-Wendel; Jean-Philippe Chippaux
Journal:  Filaria J       Date:  2003-10-24

3.  Conservative care in successful treatment of abamectin poisoning.

Authors:  Hamed Aminiahidashti; Seyed Reza Jamali; Ali Morad Heidari Gorji
Journal:  Toxicol Int       Date:  2014 Sep-Dec

4.  Intravenous veterinary ivermectin in a COVID-19 patient causing neurotoxicity.

Authors:  Stefan Porubcin; Alena Rovnakova; Ondrej Zahornacky; Pavol Jarcuska
Journal:  IDCases       Date:  2022-02-07

5.  Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination.

Authors:  Carlos J Chaccour; Kevin C Kobylinski; Quique Bassat; Teun Bousema; Chris Drakeley; Pedro Alonso; Brian D Foy
Journal:  Malar J       Date:  2013-05-07       Impact factor: 2.979

Review 6.  Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety.

Authors:  Carlos Chaccour; Felix Hammann; N Regina Rabinovich
Journal:  Malar J       Date:  2017-04-24       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.